Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ARS Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SPRY
Nasdaq
8731
https://ars-pharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ARS Pharmaceuticals Inc
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
- Apr 5th, 2024 10:30 pm
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
- Apr 3rd, 2024 1:01 pm
Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
- Apr 3rd, 2024 11:15 am
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
- Apr 1st, 2024 4:00 pm
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
- Mar 26th, 2024 12:50 pm
ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results
- Mar 21st, 2024 9:33 pm
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 21st, 2024 8:05 pm
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
- Mar 15th, 2024 10:00 am
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
- Mar 7th, 2024 9:05 pm
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
- Mar 6th, 2024 2:01 pm
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
- Feb 26th, 2024 2:01 pm
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
- Feb 22nd, 2024 2:01 pm
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term
- Feb 22nd, 2024 10:33 am
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
- Feb 20th, 2024 2:01 pm
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
- Feb 5th, 2024 2:01 pm
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Nov 9th, 2023 9:00 pm
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
- Nov 9th, 2023 4:02 pm
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
- Oct 6th, 2023 1:03 pm
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
- Oct 3rd, 2023 1:03 pm
Chief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc
- Oct 3rd, 2023 7:01 am
Scroll